Patents by Inventor Fabrice Pierre

Fabrice Pierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
    Patent number: 9062043
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: June 23, 2015
    Assignee: SENHWA BIOSCIENCES, INC.
    Inventors: Peter C. Chua, Fabrice Pierre, Jeffrey P. Whitten
  • Quinolone analogs and methods related thereto
    Patent number: 8853234
    Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: October 7, 2014
    Assignee: Senhwa Biosciences, Inc.
    Inventors: Johnny Yasuo Nagasawa, Fabrice Pierre, Mustapha Haddach, Michael Schwaebe, Levan Darjania, Jeffrey P. Whitten
  • PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
    Publication number: 20140094448
    Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.
    Type: Application
    Filed: September 13, 2013
    Publication date: April 3, 2014
    Applicant: SENHWA BIOSCIENCES, INC.
    Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas Raffaele, Suchitra Ravula, David M. Ryckman
  • Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
    Patent number: 8575177
    Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: November 5, 2013
    Assignee: Senhwa Biosciences, Inc.
    Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas B. Raffaele, Suchitra Ravula, David M. Ryckman
  • Use of cells containing a specific DNA molecule as cytopathic agents to inhibit the proliferation of cells
    Patent number: 8277798
    Abstract: The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: October 2, 2012
    Assignees: Institut National de la Recherche Agronomique, Bayerische Julius-Maximilians-Universitat Wurzburg
    Inventors: Eric Oswald, Jörg Hacker, Jean Philippe Nougayrede, Ulrich Dobrindt, Frédéric Taieb, Fabrice Pierre
  • PROTEIN KINASE MODULATORS
    Publication number: 20120208792
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: December 8, 2011
    Publication date: August 16, 2012
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Peter C. Chua, Mustapha Haddach, Johnny Y. Nagasawa, Fabrice Pierre, Jeffrey P. Whitten
  • Protein kinase modulators
    Patent number: 8168651
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: May 1, 2012
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Mustapha Haddach, Johnny Y. Nagasawa, Fabrice Pierre, Jeffrey P. Whitten
  • FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
    Publication number: 20110263581
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: February 25, 2011
    Publication date: October 27, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Peter C. CHUA, Fabrice Pierre, Jeffrey P. Whitten
  • QUINOLONE ANALOGS AND METHODS RELATED THERETO
    Publication number: 20110218184
    Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Application
    Filed: March 9, 2011
    Publication date: September 8, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Johnny Yasuo NAGASAWA, Fabrice Pierre, Mustapha Haddach, Michael Schwaebe, Levan Darjania, Jeffrey P. Whitten
  • PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
    Publication number: 20110152240
    Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.
    Type: Application
    Filed: November 15, 2010
    Publication date: June 23, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas B. Raffaele, Suchitra Ravula, David M. Ryckman
  • PYRIDINONE ANALOGS
    Publication number: 20110112086
    Abstract: The present invention provides pyridinone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing pyridinone analogs, and methods of using the same.
    Type: Application
    Filed: June 8, 2007
    Publication date: May 12, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Fabrice Pierre, Michael Schwaebe
  • Quinolone analogs and methods related thereto
    Patent number: 7928100
    Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: April 19, 2011
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Johnny Yasuo Nagasawa, Fabrice Pierre, Mustapha Haddach, Michael Schwaebe, Levan Darjania, Jeffrey P. Whitten
  • NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
    Publication number: 20110071136
    Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 24, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC
    Inventors: Mustapha HADDACH, Fabrice PIERRE
  • Therapeutic kinase modulators
    Patent number: 7910600
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: March 22, 2011
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Fabrice Pierre, Mustapha Haddach
  • NOVEL PROTEIN KINASE MODULATORS
    Publication number: 20110065698
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 17, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Fabrice PIERRE, Mustapha HADDACH, Collin F. REGAN, David M. RYCKMAN
  • TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20110065712
    Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Applicant: CYLENE PHARMACEUTICALS , INC.
    Inventors: Mustapha HADDACH, Fabrice Pierre
  • NOVEL PROTEIN KINASE MODULATORS
    Publication number: 20100298302
    Abstract: The invention provides compounds that inhibit selected kinases (Pim, Flt and/or CK2 kinases) and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain infections and immunological disorders.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 25, 2010
    Inventors: Fabrice PIERRE, Mustapha Haddach, Peter C. Chua
  • Methods of preparing quinolone analogs
    Patent number: 7834180
    Abstract: Compounds having formula 1: are produced by contacting a compound having formula (6A) with a compound having formula (7), or tautomers thereof, in the presence of a non-nucleophilic base, wherein V, A, Z, L, L1, W, X, B?, R and n are as defined herein.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: November 16, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Johnny Y. Nagasawa, Michael Schwaebe, Fabrice Pierre
  • Quinolone analogs
    Patent number: 7816406
    Abstract: The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: October 19, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Jeffrey P. Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, Johnny Y. Nagasawa, Peter Chua
  • Methods of preparing quinolone analogs
    Patent number: 7816524
    Abstract: Compounds having formula 1 are produced by contacting a compound having formula(6A) with a compound having formula (7), or tautomers thereof, in the presence of a non-nucleophilic base, wherein V, A, Z, L, L1,W, X, B?, R and N are as defined herein.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: October 19, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Johnny Y. Nagasawa, Michael Schwaebe, Fabrice Pierre